New Study Confirms Safety of Theranica's Sham Neuromodulation for Migraine with CGM Use
Study Confirms the Safety of Theranica's Nerivio® REN Wearable for Migraine Treatment
Theranica, a leader in neuromodulation therapies, has released significant findings regarding their Nerivio® REN wearable, known for its effectiveness in treating migraine. A peer-reviewed study published in the Journal of Clinical Medicine emphasizes the compatibility of this innovative device with Continuous Glucose Monitoring (CGM) systems, ensuring safety for patients dealing with both migraines and diabetes.
The study set out to alleviate concerns about the simultaneous use of the Nerivio device and CGM technologies, which have become increasingly popular among individuals managing diabetes. Specifically, the focus was on how the treatment method of Remote Electrical Neuromodulation (REN) used in the Nerivio could affect blood sugar readings from commonly utilized CGM devices such as the FreeStyle Libre® and Dexcom systems.
Background: The Need for Safe Convergence in Treatments
Migraine is a condition that affects millions of adults and adolescents worldwide, with diabetes often complicating treatment options. In the United States alone, the intersection of these two conditions is evident, affecting approximately 4.5 million people. Many of these individuals rely on CGM systems that communicate real-time glucose levels to their smartphones, making it essential that any additional treatment they use does not interfere with the accuracy of these readings.
The study methodically involved 21 adults diagnosed with diabetes, who used the Nerivio device concurrently with their CGM during a controlled 45-minute REN session. Researchers sought to discern any fluctuations in glucose readings during active treatment compared to periods when the device was inactive.
Key Findings: Promising Results
The outcomes revealed remarkable compatibility between the Nerivio and mentioned CGM devices. The median deviation in glucose measurements during treatment was merely 1.6%, comfortably within the established threshold of 5.0% set for the study. Furthermore, subgroup analyses showed consistent performance across different CGM platforms: users of the FreeStyle Libre reported a median deviation of 1.0%, while Dexcom users experienced a 1.7% deviation.
Crucially, the study noted no adverse effects or data transmission issues, confirming stable performance across both the Nerivio and CGM technologies during simultaneous usage. Christina Treppendahl, a certified headache specialist and Medical Science Liaison at Theranica, articulates the significance of these findings, stating that the study reassures both patients and healthcare providers of the safety involved in combining these technologies.
Importance for Patients Managing Multiple Conditions
The implications of this study extend beyond immediate treatment efficacy. Many patients live with multiple chronic conditions alongside migraine, necessitating the integration of various health technologies into their daily routines. Treppendahl highlights that many migraine sufferers are balancing various health issues, and our technology must seamlessly fit into their overall care strategy. The commitment to scientific rigor and patient safety underscores Theranica's role in advancing non-drug therapies for complex medical situations.
Dr. Richelle deMayo, a prominent contributor to the study, provides further insights into the unique challenges associated with treating migraines in individuals with diabetes. Given the metabolic and cardiovascular risks tied to pharmacological treatments, Theranica's device is a groundbreaking alternative that provides effective relief without the common side effects of traditional medications.
Conclusion: A New Dawn for Migraine Management with Comorbidities
The conclusion drawn from the study highlights that the simultaneous use of the Nerivio and CGM devices is not only safe but also feasible, breaking down barriers for patients navigating the complexities of managing comorbid conditions. As Theranica continues to refine and innovate within the realm of pain management technologies, the benefits of integrated care are becoming increasingly evident.
With the FDA-approved Nerivio® REN wearable, these advancements offer new hope to millions, presenting an effective, drug-free treatment for those enduring chronic migraine pain.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.